USANA Health Sciences, Inc. (NYSE:USNA) Director Sells $14,830.00 in Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director John Turman Fleming sold 500 shares of the stock in a transaction on Monday, June 9th. The shares were sold at an average price of $29.66, for a total value of $14,830.00. Following the completion of the sale, the director now owns 4,200 shares of the company’s stock, valued at $124,572. The trade was a 10.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

USANA Health Sciences Stock Up 2.7%

Shares of USNA traded up $0.82 during trading hours on Tuesday, hitting $30.63. The company had a trading volume of 46,364 shares, compared to its average volume of 134,395. USANA Health Sciences, Inc. has a 52-week low of $23.10 and a 52-week high of $48.85. The firm has a market cap of $570.33 million, a P/E ratio of 10.82, a P/E/G ratio of 0.93 and a beta of 0.63. The stock’s 50 day moving average price is $27.64 and its 200 day moving average price is $31.29.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, April 22nd. The company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.70 by $0.03. The firm had revenue of $249.54 million for the quarter, compared to analysts’ expectations of $243.08 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. During the same period in the previous year, the firm posted $0.86 EPS. On average, research analysts expect that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on USNA shares. DA Davidson dropped their price target on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, February 27th. Sidoti cut shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 18th. Finally, Wall Street Zen raised USANA Health Sciences from a “hold” rating to a “buy” rating in a report on Thursday, May 22nd.

Hedge Funds Weigh In On USANA Health Sciences

Institutional investors have recently bought and sold shares of the stock. Empowered Funds LLC bought a new position in shares of USANA Health Sciences in the 1st quarter valued at about $687,000. Petrus Trust Company LTA bought a new stake in shares of USANA Health Sciences during the first quarter valued at approximately $362,000. Jacobs Levy Equity Management Inc. raised its stake in shares of USANA Health Sciences by 46.2% during the first quarter. Jacobs Levy Equity Management Inc. now owns 188,511 shares of the company’s stock valued at $5,084,000 after acquiring an additional 59,535 shares in the last quarter. AQR Capital Management LLC increased its holdings in USANA Health Sciences by 82.8% during the first quarter. AQR Capital Management LLC now owns 21,845 shares of the company’s stock valued at $589,000 after buying an additional 9,894 shares during the period. Finally, Magnetar Financial LLC purchased a new position in USANA Health Sciences in the first quarter worth $324,000. 54.25% of the stock is owned by institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.